Therapeutic effects of tyroserleutide on lung metastasis of human hepatocellular carcinoma SsK-HEheP-1 and its mechanism affecting ICAicaM-1 and MMP-2 and -9

8Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.

Abstract

Background: Tyroserleutide (YSL) inhibits the growth and metastasis of human hepatocellular carcinoma (HCC). This paper studied the effect of YSL on metastasis of human HCC and investigated its mechanisms. Methods: In vivo, experimental lung metastasis models of human HCC SK-HEP-1 cells in nude mice were established, and In vitro, the proliferation, adhesion and invasion of SK-HEP-1 cells were detected. Results: In vivo, YSL significantly inhibited the metastasis of human HCC. In vitro, YSL significantly inhibited the proliferation, adhesion and invasion of SK-HEP-1 cells. Through analyses with reverse transcription PCR (RT-PCR) and Western blot, we observed that YSL significantly inhibited the expressions of ICAM-1 in SK-HEP-1 cells. Through RT-PCR, Western blot and zymography methods, YSL was discovered to decrease the mRNA level, protein expression and activity of MMP-2 and -9 in SK-HEP-1 cells. Conclusion: We concluded that YSL could inhibit tumor growth and metastasis of human HCC SK-HEP-1 cells.

Cite

CITATION STYLE

APA

Che, X., Lu, R., Fu, Z., Sun, Y., Zhu, Z. F., Lli, J. P., … Yao, Z. (2018). Therapeutic effects of tyroserleutide on lung metastasis of human hepatocellular carcinoma SsK-HEheP-1 and its mechanism affecting ICAicaM-1 and MMP-2 and -9. Drug Design, Development and Therapy, 12, 3357–3368. https://doi.org/10.2147/DDDT.S177126

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free